Literature DB >> 33428812

Is Europe facing an opioid epidemic: What does European monitoring data tell us?

Thomas Seyler1, Isabelle Giraudon1, André Noor1, Jane Mounteney1, Paul Griffiths1.   

Abstract

This paper addresses the question of whether Europe is facing an opioid epidemic and utilizes data from the European monitoring system on opioid use, harms and availability, to help assess the situation. Data sources covering the last decade on overdose deaths, drug treatment entrants and drug-related emergencies suggest that the health burden associated with opioid use is mostly related to the consumption of heroin - and to a lesser extent diverted opioid substitution treatment medications - and that it is primarily affecting an ageing cohort of vulnerable users, with little evidence of an increase in initiation. While opioid-related deaths are currently at much lower levels than in the United States, they still represent a large preventable health burden with differences across EU countries. There is also increasing concern related to the high availability of heroin, illicitly produced synthetic opioids and diverted opioid pain medications on the European drugs market. Trends in the latter categories are poorly monitored and we may miss signs of emerging problems. Moreover, the economic recession following the COVID-19 pandemic has a potential to lead to resurgence in opioid use and harms. SIGNIFICANCE: This paper looks at data from the European monitoring system to address the question of whether Europe is facing an opioid epidemic. It reviews available health and supply side indicators, considering the limitations of each data source. A summary of the available evidence would suggest that while opioid-related deaths in Europe represent a large preventable health burden with differences across EU countries, Europe as a whole is not facing an opioid crisis of the size and nature seen in the US.
© 2021 European Pain Federation - EFIC®.

Entities:  

Year:  2021        PMID: 33428812     DOI: 10.1002/ejp.1728

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  6 in total

1.  Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS).

Authors:  Stefania Chiappini; Rachel Vickers-Smith; Amira Guirguis; John M Corkery; Giovanni Martinotti; Daniel R Harris; Fabrizio Schifano
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-27

2.  Single and Multiple Dose PK-PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers.

Authors:  Aitana Calvo; Saioa Alonso; Esther Prieto; Ana Ascaso-Del-Rio; Jordi Ortuño; Nieves Fernandez; Antonio Portolés
Journal:  J Clin Med       Date:  2022-02-06       Impact factor: 4.241

3.  Opioid trends in Finland: a register-based nationwide follow-up study.

Authors:  Jaana Keto; Tarja Heiskanen; Katri Hamunen; Maija-Liisa Kalliomäki; Miika Linna
Journal:  Sci Rep       Date:  2022-05-04       Impact factor: 4.379

4.  Estimating the Prevalence of Recreational Opioid Use in Spain Using a Multiplier Method.

Authors:  José Pulido; Albert Sanchez-Niubo; Noelia Llorens; Juan Hoyos; Gregorio Barrio; Maria Jose Belza; Lucía Cea-Soriano; Ariadna Angulo-Brunet; Luis Sordo
Journal:  Int J Environ Res Public Health       Date:  2022-04-15       Impact factor: 3.390

5.  Nationwide Population-Based Study About Patterns of Prescription Opioid Use and Misuse Among Young Adults in Spain.

Authors:  Pilar Carrasco-Garrido; Carmen Gallardo-Pino; Isabel Jiménez-Trujillo; Valentín Hernández-Barrera; Soledad García-Gómez-Heras; Lidiane Lima Florencio; Domingo Palacios-Ceña
Journal:  Int J Public Health       Date:  2022-08-19       Impact factor: 5.100

Review 6.  Opioids in COVID-19: Two Sides of a Coin.

Authors:  Camila Vantini Capasso Palamim; Matheus Negri Boschiero; Aléthea Guimarães Faria; Felipe Eduardo Valencise; Fernando Augusto Lima Marson
Journal:  Front Pharmacol       Date:  2022-01-06       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.